Receptos Inc.
This article was originally published in Start Up
Executive Summary
Receptos isn't the only company in the G-coupled protein receptor oral MS drug arena, but it believes its proprietary S1P1 agonist will improve on Novartis' first-in-class S1P1 modulator Gilenya. Unlike Gilenya, which hits four of the five S1P receptor subtypes, the Receptos molecule binds selectively to S1P1 and has a predicted human half-life of approximately one day, potentially improving the safety profile and reducing complications for MS patients.
You may also be interested in...
Financings Of The Fortnight: Why Are Royalty-Based Financings On The Rise Again?
Plus news on recent financings by Vivus, Novira Therapeutics, Theraclone Sciences and Receptos.
Schools’ Rights Are Investment Grade At Osage University Partners
The $100 million venture fund is the first to use the rights universities hold – but rarely exercise – to make venture bets. So far, with a share of Osage’s profits as incentive, dozens of schools have been happy to share.
Start-Up Quarterly Statistics, Q1 2011
Biopharma and medical device start-ups brought in a total of $216 million in Q1 2011. Absent were any financings involving in vitro diagnostics companies. Only four acquisitions involving start-ups were completed - one in biopharma and three in the device industry. Cancer was the most popular therapeutic category among biopharma start-up alliance this quarter.